Lingke Pharma Announces New Progress in Phase II Clinical Study of Ankylosing Spondylitis

Linkco Pharmaceuticals (Hangzhou) Co.
, Ltd.
(hereinafter referred to as “Linkco Pharmaceuticals”) is an innovative drug research and development company in the clinical stage
.
The company today announced that the first patient has been dosed in a Phase II clinical trial of its selective JAK1 inhibitor LNK01001 for the treatment of autoimmune diseases in Ankylosing Spondylitis (AS)
.
The study is a randomized, double-blind, placebo-controlled Phase II study evaluating the safety and efficacy of LNK01001 capsules in patients with active ankylosing spondylitis
.
Ankylosing spondylitis is a chronic inflammatory disease with complex etiology.
It mainly affects the spine, sternum and peripheral joints of the body.
The most notable feature is the obvious or complete loss of flexibility of the spine.
The oral drug LNK01001 is the first Class 1 new drug independently developed by Lingke Pharmaceuticals.
Previously, LNK01001 has completed Phase I clinical studies of healthy subjects in China and Australia (US partners), and Phase II clinical studies for rheumatoid arthritis.
Research is currently underway
.
The lead investigator of the study, Professor Zeng Xiaofeng, director of the Department of Rheumatology and Immunology, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, said: "The pathogenesis of ankylosing spondylitis is complex and difficult to treat.
The current treatment methods are mainly to control symptoms and improve prognosis.
The data shows its therapeutic potential, and at the same time, we have seen good safety and tolerability in the clinical phase I trial.
Next, we hope to actively promote clinical research with all experts, and look forward to LNK01001 in the phase II clinical trial.
Excellent performance” “Ankylosing spondylitis is a chronic, systemic inflammatory disease for which there is currently no cure, and the clinical needs for disease management and optimal therapy are far from being met,” Chief Medical Officer of Lingke Pharmaceuticals Dr.
Xueli Guan said: "The results of Phase I of LNK01001 have demonstrated good safety and tolerability.
We will accelerate the clinical development of this innovative drug, hoping to bring new options to patients with ankylosing spondylitis.

.
"